Avera Cancer Sequencing and Analytics Protocol (ASAP)

Conditions

• Breast Cancer
• CNS Cancer
• Cancer
• Cancer Diagnosis
• Colon Cancer
• Early Detection of Cancer
• Endometrial Cancer
• GI Cancer
• Gynecologic Cancer
• Hematologic Cancer
• Lung Cancer
• Ovarian Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types. Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples. To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research. Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.

Key Dates

Start date

Nov 1, 2021

Status verified

Mar 2025

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

25,000 participants (estimated)

Primary Outcome Measure

Percent of patients participating in comprehensive molecular profiling [ Time Frame: 5 years ]

Central Contacts

• Rachel Elsey, PharmD
  605-322-3225
  [email protected]
• Avera Precision Research Team
  888-422-1410
  [email protected]

Locations (6)

Find similar trials in Marshall, MN

Related Studies

• Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
  Recruiting · M.D. Anderson Cancer Center · Miami, Florida
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  PHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
• Childhood Cancer Survivor Study
  Recruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado